Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Weight Loss, Obesity
Interventions: Protein supplementation, Diet counseling and group education lessons; Dietary Supplement · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 45 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Peripheral Neuropathy
Interventions: DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 78
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more

Conditions: Osteoporosis
Interventions: Soy Isolate, Control protein, Novasoy isoflavones, Placebo tablets; Dietary Supplement
Lead sponsor: United States Department of Agriculture (USDA); Federal
Eligibility: 65 Years and older · Female only
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Type 1 Diabetes
Interventions: Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400; Drug · Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 5
States / cities: Santa Barbara, California • Aurora, Colorado • North Kansas City, Missouri + 2 more

Conditions: Hypotension, Orthostatic, Hypotension, Spinal Cord Injuries
Interventions: Northera, Placebo; Drug · Other
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Head and Neck Cancer
Interventions: cetuximab, cisplatin; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 73
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more

Conditions: Type 2 Diabetes, T2D
Interventions: Insulin Efsitora Alfa, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 39
States / cities: Birmingham, Alabama • Sheffield, Alabama • Escondido, California + 35 more

Conditions: Ulcerative Colitis
Interventions: Basiliximab; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 25
States / cities: Anaheim, California • Roseville, California • Golden, Colorado + 22 more

Conditions: Insulin Resistance, Glucose Intolerance, Obesity, Atherosclerosis
Interventions: Reactive hyperemia peripheral artery tonometry (Rh-PAT), Blood levels for glucose, insulin, lipids and adipocytokines; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 12 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Prediabetes, Obesity
Interventions: Foods rich in high quality protein; Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Idiopathic Angioedema
Interventions: Omalizumab, Placebos; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Sclerosis
Interventions: Zenapax; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more

Conditions: HIV Infections
Interventions: Optimized Background ARVs, enfuvirtide [Fuzeon]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 21
States / cities: Hobson City, Alabama • Fountain Valley, California • Los Angeles, California + 16 more

Conditions: Crohn Disease
Interventions: BI 706321, Ustekinumab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 15
States / cities: Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more

Conditions: Retinal Vein Occlusions
Interventions: Avastin, Osurdex; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Graft Versus Host Disease (GVHD)
Interventions: Alpha-1 antitrypsin (AAT), Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 13
States / cities: Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more

Conditions: Renal Cell Carcinoma
Interventions: Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo; Drug · Biological
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 30
States / cities: La Jolla, California • Orange, California • Boca Raton, Florida + 23 more

Conditions: Peripheral Arterial Disease
Interventions: Supervised Treadmill Exercise Therapy, Health education sessions (Control), granulocyte macrophage colony stimulating factor (GM-CSF); Behavioral · Other · Drug
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Malnutrition, Nutritional Risk, Abdominal Surgery
Interventions: Protein enhanced nutrition intervention, Education Control; Dietary Supplement · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sarcoma
Interventions: filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, conventional surgery, neoadjuvant therapy, brachytherapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 0 Years to 50 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2023
U.S. locations: 212
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 155 more

Conditions: Asthma
Interventions: Placebo, Xolair; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs); Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more

Search by objective public record fields.

A High Protein Weight Loss Intervention for Sarcopenic Obesity in Women

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Soy and Isoflavones Effect on Bone

Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration

Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

Basiliximab in Moderate to Severe Ulcerative Colitis

Endothelial Function in Obese Adolescents

Veterans Achieving Weight Loss and Optimizing Resilience-Using Protein

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

Zenapax to Treat Multiple Sclerosis

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

Nutritional Perihabilitation in Older Veterans Undergoing Surgery

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents